Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

New Elite Feature: Find Similar Charts in Seconds

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Sep-22	An orexin drugs proof-of-concept in ADHD; Cues unwarranted share slide ALKS BioPharma Dive
Sep-21	How Alkermes Used Its Narcolepsy Playbook In ADHD - And Seemingly Won ALKS Investor's Business Daily
Sep-21	Alkermes Shares Rise 6.5% After Positive Phase 1b Results for ADHD Drug ALKS 7290 ALKS InvestorsHub
Sep-16	Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors ALKS Business Wire
Sep-14	Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK (tebentafusp) in previously treated advanced melanoma IMCR GlobeNewswire
Sep-11	EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review William Blair Sees More Swings In Near Term EXEL Stocktwits
Sep-11	Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay EXEL Investor's Business Daily
Sep-11	Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months EXEL InvestorsHub
Sep-10	Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program ALKS Business Wire
Sep-04	Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference KNSA GlobeNewswire
Sep-04	IBD Stock Of The Day Exelixis Hits Earnings Snag - And Then Breaks Out EXEL Investor's Business Daily
Sep-02	Cancer Stock Breaks Out To Highs; Key FDA Action On Watch EXEL Investor's Business Daily
Sep-01	Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September EXEL Business Wire
Sep-01	Immunocore to present at upcoming investor conferences IMCR GlobeNewswire
Aug-31	Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories EXEL Business Wire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)